Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

Marta Cavallin, Patrick S. Kamath, Manuela Merli, Silvano Fasolato, Pierluigi Toniutto, Francesco Salerno, Mauro Bernardi, Roberto Giulio Romanelli, Cosimo Colletta, Freddy Salinas, Antonio Di Giacomo, Lorenzo Ridola, Ezio Fornasiere, Paolo Caraceni, Filippo Morando, Salvatore Piano, Angelo Gatta, Paolo Angeli, for the Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome – 16 January 2015 – Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment.

Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma

Kim Andresen, Kirsten Muri Boberg, Hege Marie Vedeld, Hilde Honne, Peter Jebsen, Merete Hektoen, Christopher A. Wadsworth, Ole Petter Clausen, Knut E.A. Lundin, Vemund Paulsen, Aksel Foss, Øystein Mathisen, Lars Aabakken, Erik Schrumpf, Ragnhild A. Lothe, Guro E. Lind – 16 January 2015 – Early detection of the highly aggressive malignancy cholangiocarcinoma (CCA) remains a challenge but has the potential to render the tumor curable by surgical removal. This study evaluates a biomarker panel for the diagnosis of CCA by DNA methylation analyses of biliary brush samples.

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Kazuaki Chayama, Kazuo Notsumata, Masayuki Kurosaki, Ken Sato, Lino Rodrigues, Carolyn Setze, Prajakta Badri, Tami Pilot‐Matias, Regis A. Vilchez, Hiromitsu Kumada – 16 January 2015 – Approximately 2 million Japanese individuals are infected with hepatitis C virus and are at risk for cirrhosis, end‐stage liver disease, and hepatocellular carcinoma. Patients in whom interferon (IFN)/ribavirin (RBV) therapy has failed remain at risk as effective therapeutic options are limited.

A case of granulocyte‐colony stimulating factor/plasmapheresis–induced activation of granulocyte‐colony stimulating factor–positive hepatic progenitors in acute‐on‐chronic liver failure

Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States

Julie K. Heimbach, Ryutaro Hirose, Peter G. Stock, David P. Schladt, Hui Xiong, Jiannong Liu, Kim M. Olthoff, Ann Harper, Jon J. Snyder, Ajay K. Israni, Bertram L. Kasiske, W. Ray Kim – 16 January 2015 – The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC.

A case of granulocyte‐colony stimulating factor/plasmapheresis–induced activation of granulocyte‐colony stimulating factor–positive hepatic progenitors in acute‐on‐chronic liver failure

Subscribe to